Richard /ca/ Murray is CEO & President at Jounce Therapeutics, Inc. (JNCE). They have made 9 open-market trades across 1 company since 2006, most recently 2023-05-03.
CIK 0001242935
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 9 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| JNCE | SELL · 10b5-1 | 2023-04-04 | 2023-04-06 | $1.85 | $145K | +1.6% | N/A | N/A |
| JNCE | SELL | 2023-01-09 | 2023-01-11 | $1.11 | $50K | -4.0% | -11.2% | +49.6% |
| JNCE | SELL | 2022-01-07 | 2022-01-11 | $6.79 | $416K | -2.4% | +21.2% | +0.0% |
| JNCE | SELL | 2021-01-21 | 2021-01-25 | $12.06 | $808K | -1.0% | -16.0% | -25.5% |
| JNCE | SELL | 2021-01-15 | 2021-01-20 | $9.72 | $1.3M | +7.1% | +1.1% | -20.9% |
| JNCE | SELL | 2021-01-07 | 2021-01-11 | $6.85 | $220K | +74.8% | +72.1% | +27.2% |
| JNCE | SELL | 2020-01-07 | 2020-01-10 | $7.78 | $56K | -12.1% | -20.7% | -36.1% |
| JNCE | SELL | 2019-12-23 | 2019-12-26 | $8.37 | $670K | -11.8% | -26.2% | -43.4% |
| JNCE | SELL | 2018-03-08 | 2018-03-12 | $25.10 | $820K | -9.2% | -24.7% | -73.1% |
| JNCE | SELL | 2018-03-05 | 2018-03-07 | $21.56 | $443K | +21.5% | -17.2% | -65.9% |
| PDLI | SELL · 10b5-1 | 2006-03-03 | 2006-03-07 | $32.00 | $480K | -11.2% | -0.3% | -0.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.